Addition of baricitinib to mainstay of treatment improves signs and symptoms of atopic dermatitis, study finds
![Atopic dermatitis on hands](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20100%2056%22%3E%3C/svg%3E)
Adding the oral selective Janus kinase 1 and 2 inhibitor, baricitinib, to topical corticosteroid treatment significantly improves the signs and symptoms of moderate-to-severe atopic dermatitis, a phase III study in JAMA Dermatology has suggested.…
Published: 15 October 2020